Skip to main content

Advertisement

Table 3 Clinical and psychosocial outcomes and quality of life according to the level of care coordination

From: Association between perception of care coordination and health outcomes in Korean cancer survivors

Measurement tools(range)Overall (N = 1306)Uncoordinated group (N = 167)Intermediate group (N = 494)Coordinated group (N = 645)P-for trend*
N (%)
Mean ± SD
N (%)
Mean ± SD
N (%)
Mean ± SD
N (%)
Mean ± SD
New comorbidity after cancer diagnosis 396 (30.3)55 (32.9)159 (32.2)182 (28.2)0.039
Type of new Comorbidity< 0.001
 Cerebrovascular 16 (1.2)3 (1.8)8 (1.6)5 (0.8) 
 Hypertension 65 (5.0)10 (6.0)26 (5.3)29 (4.5) 
 Diabetes mellitus 23 (1.8)1 (0.6)9 (1.8)13 (2.0) 
 Dyslipidemia 105 (8.0)15 (9.0)39 (7.9)51 (7.9) 
 Mental disorder 14 (1.1)2 (1.2)4 (0.8)8 (1.2) 
 Othersa 173 (13.2)24 (14.4)73 (14.8)76 (11.8) 
No of new comorbidity0–40.42 ± 0.720.44 ± 0.750.48 ± 0.790.37 ± 0.660.012
No of clinic visiting, yearly1–142.4 ± 1.62.8 ± 1.92.5 ± 1.52.3 ± 1.60.004
EQ_VASb0–10068.1 ± 16.764.6 ± 18.167.1 ± 17.369.8 ± 15.7< 0.001
EORTC QLQ-C30 
Global health status/QOL0–10066.4 ± 18.763.7 ± 20.064.8 ± 19.068.4 ± 17.90.001
Functional scalesb
 Physical functioning0–10081.1 ± 16.277.4 ± 15.780.1 ± 16.482.8 ± 16.0< 0.001
 Role functioning0–10086.4 ± 20.181.0 ± 22.583.5 ± 22.090.0 ± 17.0< 0.001
 Emotional functioning0–10080.0 ± 20.273.1 ± 22.576.1 ± 21.184.8 ± 17.6< 0.001
 Cognitive functioning0–10075.6 ± 19.371.4 ± 19.274.8 ± 19.777.3 ± 18.90.001
 Social functioning0–10080.0 ± 23.277.3 ± 25.676.8 ± 23.783.1 ± 21.7< 0.001
Symptom scalesc
 Fatigue0–10033.8 ± 24.643.1 ± 24.137.4 ± 25.928.7 ± 22.4< 0.001
 Nausea and vomiting0–10010.3 ± 16.314.4 ± 19.911.7 ± 17.28.1 ± 14.2< 0.001
 Pain0–10017.8 ± 22.021.6 ± 22.921.4 ± 24.114.1 ± 19.2< 0.001
 Dyspnea0–10016.7 ± 22.323.6 ± 24.919.6 ± 22.412.7 ± 20.7< 0.001
 Insomnia0–10029.5 ± 32.138.5 ± 31.930.2 ± 31.326.6 ± 32.3< 0.001
 Appetite loss0–10013.9 ± 24.020.8 ± 24.414.9 ± 27.511.4 ± 20.3< 0.001
 Constipation0–10018.6 ± 25.125.0 ± 26.821.7 ± 26.314.6 ± 23.1< 0.001
 Diarrhea0–10021.7 ± 25.326.1 ± 29.123.5 ± 25.519.2 ± 23.8< 0.001
 Financial difficulties0–10018.4 ± 26.920.6 ± 29.919.7 ± 27.016.9 ± 25.90.086
K-FCRI
 Triggersc0–3213.1 ± 6.815.1 ± 7.313.6 ± 7.012.0 ± 6.3< 0.001
 Severityc0–3611.2 ± 7.313.6 ± 7.412.4 ± 7.29.6 ± 6.9< 0.001
 Psychological distressc0–164.2 ± 3.95.3 ± 3.94.6 ± 4.13.5 ± 3.6< 0.001
 Functional impairmentc0–245.0 ± 5.45.2 ± 5.25.1 ± 5.74.9 ± 5.30.920
 Coping strategiesb0–3619.1 ± 7.618.3 ± 8.218.6 ± 7.119.9 ± 7.60.005
 Insightc0–121.3 ± 2.11.8 ± 2.71.6 ± 2.21.0 ± 1.80.014
 Reassuranceb0–125.0 ± 3.24.7 ± 2.94.9 ± 3.25.1 ± 3.40.129
  1. Data were presented as mean value ± standard deviation, number, or number (percentage)
  2. EQ-VAS EuroQoL Visual Analogue Scale, EORTC QLQ-C30 The European Organization for Research and Treatment of Cancer 30-item quality of life questionnaire, QOL quality of life, K-FCRI Korean version of fear of cancer recurrence index. *P values for trend were obtained by linear regression analysis after adjusting for age, sex, cancer site, marital status, cancer stage, treatment modality, type of care providers and duration since cancer diagnosis. aOthers included thyroid disease, liver disease, lung disease, osteoporosis, lymphedema, peripheral neuropathy, and anemia. bHigher score means better health status. cLower score means better health status